Dexcom CONNECT Trial Validates CGM Benefits in Type 2 Non-Insulin Patients

What happened

Dexcom announced results from the CONNECT randomized controlled trial, demonstrating that use of its G7 CGM leads to statistically significant reductions in A1C and improved glucose control in people with Type 2 diabetes not using insulin, compared to routine blood glucose monitoring. The data, presented at a major medical conference, provide strong clinical evidence supporting Dexcom's expansion into the large and underserved non-insulin Type 2 market, a key pillar of its growth strategy. While the stock has been pressured by GLP-1 fears and an FDA warning letter, this trial mitigates the risk that CGM adoption is limited to insulin users and reinforces the narrative that CGM complements GLP-1 therapy. However, the company still faces execution challenges in lifting gross margins to the 63-64% target and resolving quality system deficiencies. The study is a positive catalyst for the Type 2 thesis but does not eliminate regulatory or competitive headwinds.

Implication

The CONNECT study provides concrete clinical proof that Dexcom's CGM improves outcomes in Type 2 patients not on insulin, reducing the risk that growth is limited to insulin users. This strengthens the bull case that Type 2/non-insulin and OTC/wellness volumes can sustain mid-teens revenue growth, supporting the 2026 margin guidance. Combined with manufacturing scale and 15-day sensor economics, the data supports the base case implied value of $80 and could tilt probabilities toward the bull scenario if regulatory and pricing headwinds abate. However, investors should monitor detailed 2026 guidance and FDA inspection outcomes for confirmation.

Thesis delta

The CONNECT trial adds robust clinical evidence that the non-insulin Type 2 segment is a viable and significant growth driver for Dexcom, reducing reliance on insulin users and supporting the company's broader metabolic health platform. This likely increases the probability of the bull scenario, where revenue grows 14-15% with margins above 64%, though manufacturing and regulatory risks remain. The thesis shift is that the addressable market is larger and more evidence-backed than previously assumed, warranting a higher valuation multiple if execution follows.